PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D growth above 1.5x AGEN's 8.75%. Michael Burry would check for spending discipline.
3110.63%
G&A growth above 1.5x AGEN's 16.87%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses growth above 1.5x AGEN's 12.96%. Michael Burry would check for inefficiency.
11227.11%
Total costs growth above 1.5x AGEN's 14.78%. Michael Burry would check for inefficiency.
26362.71%
Interest expense growth above 1.5x AGEN's 0.96%. Michael Burry would check for over-leverage.
-84.19%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-40.83%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-16129.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
-16129.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-12933.18%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
24.22%
Share count reduction below 50% of AGEN's 2.74%. Michael Burry would check for concerns.
24.22%
Diluted share reduction below 50% of AGEN's 2.73%. Michael Burry would check for concerns.